Andrea F. Wainer - 23 Feb 2024 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Signature
/s/ Andrea F. Wainer by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
23 Feb 2024
Net transactions value
-$750,750
Form type
4
Filing time
27 Feb 2024, 18:13:27 UTC
Previous filing
23 Feb 2024
Next filing
04 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Options Exercise $749,250 +12,500 +16% $59.94 91,204 23 Feb 2024 Direct
transaction ABT Common shares without par value Sale $1,500,000 -12,500 -14% $120.00 78,704 23 Feb 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Options Exercise $0 -12,500 -27% $0.000000 34,449 23 Feb 2024 Common Shares 12,500 $59.94 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.